Cargando…

A prospective observational study of patient-reported functioning and quality of life in advanced and metastatic breast cancer utilizing a novel mobile application

PURPOSE: To assess and describe patient-reported outcomes (PROs) in women with locally advanced/unresectable or metastatic breast cancer (aBC/mBC) with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR + /HER2 −) status receiving palbociclib combination therapy in a US...

Descripción completa

Detalles Bibliográficos
Autores principales:	Richardson, David, Zhan, Lin, Mahtani, Reshma, McRoy, Lynn, Mitra, Debanjali, Reynolds, Maria, Odom, Dawn, Hollis, Kelly, Kaye, James A., Jones, Cheryl, Hargis, Jeffrey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8062359/ https://www.ncbi.nlm.nih.gov/pubmed/33428072 http://dx.doi.org/10.1007/s10549-020-06082-7

Ejemplares similares

Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer
por: Wilson, Florence R., et al.
Publicado: (2017)

A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer
por: Modi, Shanu, et al.
Publicado: (2013)

Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)
por: Finn, Richard S., et al.
Publicado: (2020)

Diagnostic accuracy, clinical utility and influence on decision‐making of a methylation urine biomarker test in the surveillance of non‐muscle‐invasive bladder cancer
por: D'Andrea, David, et al.
Publicado: (2019)

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
por: Lin, Nancy U., et al.
Publicado: (2012)

Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice
por: Brufsky, Adam, et al.
Publicado: (2021)

Neurodynamic mobilization and foam rolling improved delayed-onset muscle soreness in a healthy adult population: a randomized controlled clinical trial
por: Romero-Moraleda, Blanca, et al.
Publicado: (2017)

Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis
por: Brufsky, Adam, et al.
Publicado: (2022)

A Phase II Trial of Sorafenib in Metastatic Melanoma with Tissue Correlates
por: Ott, Patrick A., et al.
Publicado: (2010)

Chemotherapy use near the end-of-life in patients with metastatic breast cancer
por: Edman Kessler, Luisa, et al.
Publicado: (2020)

Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer
por: Souwer, E. T. D., et al.
Publicado: (2023)

Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2023)

A Phase II Trial of Selinexor (KPT‐330) for Metastatic Triple‐Negative Breast Cancer
por: Shafique, Michael, et al.
Publicado: (2019)

HER2-targeted therapy influences CTC status in metastatic breast cancer
por: Deutsch, Thomas M., et al.
Publicado: (2020)

Exploring patients’ experience and perception of being diagnosed with bladder cancer: a mixed‐methods approach
por: Tan, Wei Shen, et al.
Publicado: (2020)

Patient-reported pain severity, pain interference and health status in HR+/HER2− advanced/metastatic breast cancer
por: Wood, Robert, et al.
Publicado: (2017)

Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer
por: Pezo, Rossanna C., et al.
Publicado: (2017)

The development and initial evaluation of the Diarrhoea Management Diary (DMD) in patients with metastatic breast cancer
por: Harder, Helena, et al.
Publicado: (2020)

Utilization of bioimpedance spectroscopy in the prevention of chronic breast cancer-related lymphedema
por: Kaufman, David I., et al.
Publicado: (2017)

Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2021)

Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer
por: Rugo, Hope S, et al.
Publicado: (2023)

Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer
por: Vriens, B. E. P. J., et al.
Publicado: (2017)

Single arm, phase two study of low-dose metronomic eribulin in metastatic breast cancer
por: Chalasani, Pavani, et al.
Publicado: (2021)

CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin‐C vs surgical management in low‐risk non‐muscle‐invasive bladder cancer
por: Mostafid, A. Hugh, et al.
Publicado: (2020)

Mobile Geriatric Teams – A Cost-Effective Way Of Improving Patient Safety And Reducing Traditional Healthcare Utilization Among The Frail Elderly? A Randomized Controlled Trial
por: Fristedt, Sofi, et al.
Publicado: (2019)

Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer
por: De Boer, Richard H., et al.
Publicado: (2012)

Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies
por: Twelves, Chris, et al.
Publicado: (2014)

Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study
por: Tolaney, Sara M., et al.
Publicado: (2016)

Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase
por: Sachdev, Jasgit C., et al.
Publicado: (2020)

Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study
por: Boman, Caroline, et al.
Publicado: (2022)

2224: Characterizing vigilant thoughts and behaviors that disrupt sleep in veterans and utilization of cognitive techniques
por: Katherine Howell, Mary, et al.
Publicado: (2018)

Exergames for women with fibromyalgia: a randomised controlled trial to evaluate the effects on mobility skills, balance and fear of falling
por: Collado-Mateo, Daniel, et al.
Publicado: (2017)

A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer
por: Ma, Cynthia X., et al.
Publicado: (2012)

Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer
por: Haddad, Tufia C., et al.
Publicado: (2017)

A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns
por: Tzikas, Anna-Karin, et al.
Publicado: (2020)

Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer
por: Walter, Vincent, et al.
Publicado: (2020)

Average duration of prior treatment lines predicts clinical benefit to eribulin chemotherapy in patients with metastatic breast cancer
por: Coe, Faye, et al.
Publicado: (2021)

2396: Utility of the Modified Barium Swallow Impairment Profile as an outcome measure in oculopharyngeal muscular dystrophy
por: Youssof, Sarah, et al.
Publicado: (2018)

nab-Paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis
por: O’Shaughnessy, Joyce, et al.
Publicado: (2013)

Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer
por: Yu, Y. F., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_aq7kp18i9mu2r34jggl2o0otci